Abstract
Influenza is a cause of significant morbidity and mortality in young children. It is associated with high annual attack rates as well as being responsible for frequent outpatient visits and hospitalisations. Children aged <2 years are at the highest risk for serious illness or death during the influenza season. The neuraminidase inhibitor oseltamivir has been proven to reduce the duration and severity of illness when treatment is commenced within 48 hours of symptom onset. The H1N1 pandemic of 2009 prompted temporary emergency authorisation of oseltamivir use in infants aged <1 year in the USA. In December 2012, Food and Drug Administration (FDA) reinstated approval of oseltamivir to treat children younger than 1 year old including neonates who have shown symptoms of influenza for less than 48 hours. Current data on the use of oseltamivir in neonates and infants are limited. In this review, we evaluated accumulated data on oseltamivir use in newborns, infants and young children with a special focus on pharmacokinetics, efficacy and safety.
Keywords: Children, infants, neonates, oseltamivir, pharmacokinetics, safety.
Infectious Disorders - Drug Targets
Title:Oseltamivir in Neonates, Infants and Young Children: A Focus on Clinical Pharmacology
Volume: 13 Issue: 1
Author(s): Eda Karadag-Oncel and Mehmet Ceyhan
Affiliation:
Keywords: Children, infants, neonates, oseltamivir, pharmacokinetics, safety.
Abstract: Influenza is a cause of significant morbidity and mortality in young children. It is associated with high annual attack rates as well as being responsible for frequent outpatient visits and hospitalisations. Children aged <2 years are at the highest risk for serious illness or death during the influenza season. The neuraminidase inhibitor oseltamivir has been proven to reduce the duration and severity of illness when treatment is commenced within 48 hours of symptom onset. The H1N1 pandemic of 2009 prompted temporary emergency authorisation of oseltamivir use in infants aged <1 year in the USA. In December 2012, Food and Drug Administration (FDA) reinstated approval of oseltamivir to treat children younger than 1 year old including neonates who have shown symptoms of influenza for less than 48 hours. Current data on the use of oseltamivir in neonates and infants are limited. In this review, we evaluated accumulated data on oseltamivir use in newborns, infants and young children with a special focus on pharmacokinetics, efficacy and safety.
Export Options
About this article
Cite this article as:
Karadag-Oncel Eda and Ceyhan Mehmet, Oseltamivir in Neonates, Infants and Young Children: A Focus on Clinical Pharmacology, Infectious Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/18715265112129990004
DOI https://dx.doi.org/10.2174/18715265112129990004 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies
Current Alzheimer Research 14-3-3 Protein in CSF Reflects SIV-Mediated Pre-Synaptic Damage
Current HIV Research A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody
Current Drug Metabolism The Potential Health Benefits of Algae and Micro Algae in Medicine: A Review on Spirulina platensis
Current Nutrition & Food Science Bioinformatics Comparison of G Protein of Isfahan Virus with the Same Proteins of Two Other Closely Related Viruses of the Genus Vesiculovirus
Protein & Peptide Letters First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and - Preliminary Dynamics of Neuroprotectant 2-Iminobiotin in Healthy Subjects
Current Clinical Pharmacology Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Hypocholesterolemia
Current Vascular Pharmacology Artificial Blood: A Futuristic Dimension of Modern Day Transfusion Sciences
Cardiovascular & Hematological Agents in Medicinal Chemistry Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases
Current Pharmaceutical Design Synthesis and Biological Evaluation of a Series of 4-(arylamido/imidoalkyl)- 5-(arylideno- 4-oxo-2-thio-imidazolidinyl)-N-(methyl-phenyl-imino) Acridinium Iodides as Potential Antiviral Agents
Letters in Drug Design & Discovery Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design A DNA Barcoding Based Study to Identify Main Mosquito Species in Taiwan and its Difference from Those in Mainland China
Combinatorial Chemistry & High Throughput Screening Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Pharmacological Modulation of the State of Awareness in Patients with Disorders of Consciousness: An Overview
Current Pharmaceutical Design Inhibition of Membrane Fusion as a Target for Antiviral Therapy
Anti-Infective Agents in Medicinal Chemistry